Method for separating and / or detecting roxatidine acetate and related substances thereof

Through high performance liquid chromatography combined with octadecylsilane bonded silica gel chromatography column, the problem of separation and detection of rosatidine acetate and related substances was solved, and drug quality control and drug safety guarantee was achieved. Suitable for industrial production.

CN119086746APending Publication Date: 2024-12-06BEIJING AOHE DRUG RES INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411196237.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

It is difficult to effectively isolate and detect rosatidin acetate and its related substances in the prior art, affecting the quality and safety of drugs, leading to possible adverse reactions and clinical drug effectiveness issues.

Method used

Using high-performance liquid chromatography, using octadecylsilane-bonded silica gel chromatography column, the mobile phase consists of potassium dihydrogen phosphate solution-methanol-acetonitrile and methanol-acetonitrile. Through gradient elution procedure, the acetic acid of rosatidi Effective separation and detection of esters and related substances.

Benefits of technology

It has achieved effective separation and detection of rosatidine acetate and its related substances, ensuring controllable drug quality, reducing adverse reactions, ensuring drug safety, and saving time and cost, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119086746A_ABST
    Figure CN119086746A_ABST
Patent Text Reader

Abstract

The invention provides a method for separating and / or detecting roxatidine acetate and related substances thereof. A chromatographic column stationary phase of the high performance liquid chromatography is octadecylsilane chemically bonded silica, a mobile phase is composed of a phase A and a phase B, the phase A is monopotassium phosphate solution-methanol-acetonitrile, the phase B is methanol-acetonitrile, the mobile phase is gradient elution, and the detection wavelength is 250nm. The related substance is selected from any one or a combination of a related substance 1, a related substance 2, a related substance 3, a related substance 4, a related substance 5, a related substance 6, a related substance 7 and a related substance 8. The method provided by the invention can realize efficient separation and detection of roxatidine acetate and related substances thereof, and can effectively control the drug quality of a roxatidine acetate hydrochloride preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug analysis, and in particular to a method for separating and / or detecting roxatidine acetate and related substances thereof. Background Art

[0002] Roxatidine is a histamine H2 receptor antagonist. Roxatidine acetate hydrochloride is deacetylated and converted into the metabolite roxatidine by esterification in the body. Both roxatidine acetate hydrochloride and roxatidine have pharmacological activity and can effectively inhibit the basal gastric acid secretion and gastric acid secretion caused by stimulation in animals. Roxatidine acetate hydrochloride for injection is suitable for low-risk patients with upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.).

[0003] The chemical name of roxatidine acetate hydrochloride is 2-acetoxy-N-[3-[3-(1-piperidinylmethylphenyl)oxy]propyl]acetamide hydrochloride, and the chemical structure is as follows:

[0004]

[0005] The presence of related substances is directly related to the quality and safety of drugs. Related substances include related substances brought in by drug raw materials, related substances generated during the process, and related substances related to degradation, etc., which will directly affect the purity and quality of the drug, and may even cause serious adverse reactions, affecting the effectiveness and safety of clinical drugs. In order to improve the quality of roxatidine acetate hydrochloride preparations and ensure the safety and effectiveness of clinical drugs, it is necessary to fully study the related substances and develop applicable separation and detection methods to control the related substances within the safety limit, achieve controllable drug quality, and ensure the safety and effectiveness of clinical drugs. Summary of the invention

[0006] The object of one aspect of the present invention is to provide a method for separating and / or detecting roxatidine acetate and its related substances, which comprises the following features: high performance liquid chromatography is adopted, the stationary phase of the chromatographic column is octadecylsilane bonded silica gel, the mobile phase is composed of phase A and phase B, phase A is potassium dihydrogen phosphate solution-methanol-acetonitrile, phase B is methanol-acetonitrile, the mobile phase is gradient elution, and the related substances are selected from any one of related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8 or a combination thereof:

[0007]

[0008]

[0009] In the preferred technical scheme of the present invention, the octadecylsilane bonded silica gel chromatographic column is commercially available, preferably an octadecylsilane bonded silica gel column produced by any one of ThermoFisher, YMC, Phenomenex, ES, Merck, Agilent, Kromasil, Agela, Techmate, and Waters.

[0010] In the preferred technical scheme of the present invention, the octadecylsilane bonded silica gel chromatographic column is selected from Eclipse PlusC18, Kromasil 100-5-C18, Kromasil Eternity-5-C18, Kromasil EternityXT-10-C18, Kromasil100-10-C18, Kromasil 300-5-C18, YMC Pack ODS-AQ C18, YMC Pack ODS-AMC18, YMC Triart C18, Phenomenex kinetex C18, Titank C18, ES-C18, Epic C18, ZORBAXSB-C18, ZORBAX 300SB-C18, Poroshell 120EC-C18, XDB-C18, TC-C18, Extend-C18, Bonshell C18, Bonshell ASB C18, Venusil HLP C18, Venusil C18 Plus, Venusil XBPC18 (A), Venusil XBP C18 (B), Venusil MP C18, Innoval Neo XD C18, Techmate C18-ST, Techmate C18-STⅡ, Techmate CI8 UG, Welch Ultimate XS-C18, Waters Atlantis T3, Waters Xbridge C18, or any combination thereof.

[0011] In a preferred technical solution of the present invention, the octadecylsilane bonded silica gel chromatographic column is Kromasil 100-5-C18.

[0012] In the preferred technical solution of the present invention, the octadecylsilane bonded silica gel chromatographic column is Kromasil 100-5-C18, 4.6 mm×250 mm, 5 μm.

[0013] In a preferred technical solution of the present invention, the column temperature of the chromatographic column is 25°C-45°C, preferably 30°C-40°C.

[0014] In a preferred technical solution of the present invention, the concentration of the potassium dihydrogen phosphate solution in the mobile phase A is 0.01 mol / L-0.3 mol / L, preferably 0.05 mol / L-0.15 mol / L, and more preferably 0.05 mol / L.

[0015] In a preferred technical solution of the present invention, the pH value of the potassium dihydrogen phosphate solution in the mobile phase A is adjusted to 5.5-6.5, preferably to 5.8-6.2; particularly preferably, potassium hydroxide solution is used to adjust the pH value of the potassium dihydrogen phosphate solution.

[0016] In the preferred technical solution of the present invention, the volume ratio of potassium dihydrogen phosphate solution: methanol: acetonitrile in the mobile phase A is 81-99: 9.5-0.5: 9.5-0.5, preferably 84-96: 8-2: 8-2, and more preferably 88-92: 6-4: 6-4.

[0017] In a preferred technical solution of the present invention, the volume ratio of methanol to acetonitrile in the mobile phase B is 40-60:60-40, preferably 45-55:55-45, and more preferably 50:50.

[0018] In the preferred technical solution of the present invention, the gradient elution procedure is:

[0019]

[0020] Preferably, the gradient elution procedure is:

[0021]

[0022]

[0023] In the preferred technical solution of the present invention, the flow rate of the mobile phase is 0.8ml / min-1.4ml / min, preferably 1.0ml / min-1.2ml / min.

[0024] In a preferred technical solution of the present invention, the injection volume of the method is 25 μl-75 μl, preferably 40 μl-60 μl, and more preferably 50 μl.

[0025] In the preferred technical solution of the present invention, the method is equipped with an ultraviolet detector, and the detection wavelength of the ultraviolet detector is 190nm-210nm, preferably 195nm-205nm.

[0026] In the preferred technical scheme of the present invention, the order of peaks is related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, roxatidine acetate, related substance 6, related substance 7, and related substance 8, wherein the separation between roxatidine acetate and the related substance 5 peak, the related substance 6 peak, and between the peaks of each related substance is greater than 1.5.

[0027] In the preferred technical solution of the present invention, the method comprises the following steps:

[0028] 1) Solution preparation:

[0029] Solvent: water-acetonitrile (80:20);

[0030] Test solution: Take an appropriate amount of roxatidine acetate, dissolve it in a solvent and dilute it to make a solution containing about 2 mg of roxatidine acetate per 1 ml;

[0031] System suitability solution: Take appropriate amounts of related substances 1-8 and roxatidine acetate, dissolve and dilute with solvent to prepare a mixed solution containing about 2 mg of roxatidine acetate and about 2-4 μg of related substances 1 to 8 per 1 ml;

[0032] 2) An octadecylsilane bonded silica gel column was used as the stationary phase, the column temperature was 30°C-40°C, the mobile phase consisted of phase A and phase B, phase A was 0.05 mol / L potassium dihydrogen phosphate solution (pH adjusted to 5.8-6.2 with potassium hydroxide solution)-methanol-acetonitrile (92-88:4-6:4-6), phase B was methanol-acetonitrile (50:50), the mobile phase was gradient elution, and the gradient elution program was as follows:

[0033]

[0034] , inject the eluted sample into the liquid chromatograph with an injection volume of 50 μl, the detection wavelength of the UV detector is 195-205 nm, the flow rate is 1.0 ml-1.2 ml per minute, elute and record the chromatogram.

[0035] In the preferred technical solution of the present invention, the method comprises the following steps:

[0036] 1) Solution preparation:

[0037] Solvent: water-acetonitrile (80:20);

[0038] Test solution: Take an appropriate amount of roxatidine acetate, dissolve it in a solvent and dilute it to make a solution containing about 2 mg of roxatidine acetate per 1 ml;

[0039] System suitability solution: Take appropriate amounts of related substances 1-8 and roxatidine acetate, dissolve and dilute with solvent to prepare a mixed solution containing about 2 mg of roxatidine acetate and about 2-4 μg of related substances 1 to 8 per 1 ml;

[0040] 2) The chromatographic column Kromasil 100-5-C18, 4.6 mm × 250 mm, 5 μm was used as the stationary phase, the column temperature was 35°C, the mobile phase consisted of phase A and phase B, phase A was 0.05 mol / L potassium dihydrogen phosphate solution (pH adjusted to 6.0 with potassium hydroxide solution)-methanol-acetonitrile (90:5:5), phase B was methanol-acetonitrile (50:50), the mobile phase was gradient elution, and the gradient elution program was as follows:

[0041]

[0042] , inject the eluted sample into the liquid chromatograph with an injection volume of 50 μl, the detection wavelength of the UV detector is 200 nm, the flow rate is 1.1 ml per minute, elute and record the chromatogram.

[0043] Another object of the present invention is to provide an application of the method described in the present invention in separating and / or detecting roxatidine acetate and its related substances.

[0044] Unless otherwise specified, when the present invention relates to the percentage between liquids, the percentage is volume / volume percentage; when the present invention relates to the percentage between liquids and solids, the percentage is volume / weight percentage (ml / g); when the present invention relates to the percentage between solids and liquids, the percentage is weight / volume percentage (g / ml); the rest are weight / weight percentages.

[0045] Compared with the prior art, the present invention has the following beneficial effects:

[0046] (1) The present invention scientifically screens and optimizes the elution conditions of high performance liquid chromatography, and realizes the effective separation and detection of 9 compounds with similar structures and difficult to separate, such as roxatidine acetate and its related substances. The separation effect is good, and the drug quality control can be effectively carried out, and the adverse reactions that may occur in drug clinical trials and treatments can be reduced, thereby ensuring the effectiveness and safety of patients' medication.

[0047] (2) The method of the present invention is time-saving, can save time cost, improve economic benefits, and is suitable for industrial and large-scale production. The mobile phase of the present invention is easy to prepare and can be prepared according to conventional methods.

[0048] (3) The method of the present invention has strong specificity, the related substances and the blank solvent do not interfere with each other, and the separation between the peaks of each component is greater than 1.5; the chromatographic conditions of the present invention have high sensitivity in detecting related substances; when the chromatographic conditions change slightly, the separation of the peaks of each component is not affected, and the durability of the method is good. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 It is the high performance liquid chromatogram of Comparative Example 1.

[0050] Figure 2 It is the high performance liquid chromatogram of Comparative Example 2.

[0051] Figure 3 It is the high performance liquid chromatogram of Example 1.

[0052] Figure 4 It is the HPLC chromatogram of the mixed solution of Example 2. DETAILED DESCRIPTION

[0053] To make the purpose, technical solution and advantages of the present invention more clear, the embodiments of the present invention will be described in detail with reference to the accompanying drawings. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other arbitrarily without conflict.

[0054] Comparative Example 1 HPLC Separation and Detection of Roxatidine Acetate and Its Related Substances

[0055] Liquid chromatograph: Shimadzu LC-20A

[0056] Column: Kromasil 100-5-C18, 4.6 mm × 250 mm, 5 μm

[0057] Mobile phase A: 0.05 M potassium dihydrogen phosphate solution (adjust pH to 6.0 with potassium hydroxide solution)

[0058] Mobile phase B: acetonitrile

[0059] Flow rate: 1.1ml / min

[0060] Column temperature: 35°C

[0061] UV detector detection wavelength: 200nm

[0062] Injection volume: 50 μl

[0063] Solvent: water-acetonitrile (80:20)

[0064] The gradient elution program is as follows:

[0065]

[0066] Mixed solution: Take appropriate amounts of roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8, dissolve and dilute with a solvent to prepare a mixed solution containing about 1 mg of roxatidine acetate and about 1-2 μg of each of related substances 1 to related substances 8 per 1 ml;

[0067] The chromatographic results of the mixed solution are shown in Figure 1 .

[0068] The results showed that related substance 6 and related substance 7 could not be effectively separated, the peak shapes of the impurity peaks were poor, the responses were low, and the product quality could not be controlled.

[0069] Comparative Example 2 HPLC Separation and Detection of Roxatidine Acetate and Its Related Substances

[0070] Liquid chromatograph: Shimadzu LC-20A

[0071] Column: Kromasil 100-5-C18, 4.6 mm × 250 mm, 5 μm

[0072] Mobile phase A: 0.05 M potassium dihydrogen phosphate solution (adjust pH to 6.0 with potassium hydroxide solution)-acetonitrile (90:10)

[0073] Mobile phase B: methanol-acetonitrile (50:50)

[0074] Flow rate: 1.1ml / min

[0075] Column temperature: 35°C

[0076] UV detector detection wavelength: 200nm

[0077] Injection volume: 50 μl

[0078] Solvent: water-acetonitrile (80:20)

[0079] The gradient elution program is as follows:

[0080]

[0081] Mixed solution: Take appropriate amounts of roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8, dissolve and dilute with a solvent to prepare a mixed solution containing about 2 mg of roxatidine acetate and about 2-4 μg of each of related substances 1 to related substances 8 per 1 ml;

[0082] The chromatographic results of the mixed solution are shown in Figure 2 .

[0083] The results showed that related substance 6 and related substance 7 could not be effectively separated, the peak shapes of multiple impurity peaks were poor, and the product quality could not be controlled.

[0084] Example 1 HPLC separation and detection of roxatidine acetate and its related substances

[0085] Liquid chromatograph: Shimadzu LC-20A

[0086] Column: Kromasil 100-5-C18, 4.6 mm × 250 mm, 5 μm

[0087] Mobile phase A: 0.05 M potassium dihydrogen phosphate solution (adjust pH to 6.0 with potassium hydroxide solution)-methanol-acetonitrile (90:5:5)

[0088] Mobile phase B: methanol-acetonitrile (50:50)

[0089] Flow rate: 1.1ml / min

[0090] Column temperature: 35°C

[0091] UV detector detection wavelength: 200nm

[0092] Injection volume: 50 μl

[0093] Solvent: water-acetonitrile (80:20)

[0094] The gradient elution program is as follows:

[0095]

[0096] Mixed solution: Take appropriate amounts of roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8, dissolve and dilute with a solvent to prepare a mixed solution containing approximately 2 mg of roxatidine acetate and approximately 2-4 μg of each of related substances 1 to related substances 8 per 1 ml.

[0097] The chromatographic results of the mixed solution are shown in Figure 3 .

[0098] The results showed that under this system, roxatidine acetate and adjacent impurities, as well as the impurities themselves, could be well separated, meeting product control requirements.

[0099] Example 2 Specificity of the HPLC separation and detection method of the present invention

[0100] The chromatographic conditions were the same as in Example 1.

[0101] Localization solution: Take appropriate amounts of roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8, dissolve and dilute with a solvent to prepare a solution containing approximately 2 mg of roxatidine acetate and approximately 10-40 μg of each of related substances 1 to related substances 8 per 1 ml.

[0102] Mixed solution: Take appropriate amounts of roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8, dissolve and dilute with a solvent to prepare a mixed solution containing approximately 2 mg of roxatidine acetate and approximately 2-4 μg of each of related substances 1 to related substances 8 per 1 ml.

[0103] The chromatographic results of the mixed solution are shown in Table 1 and Figure 4 .

[0104] Table 1

[0105]

[0106] The results showed that the separation between the chromatographic peaks of related substances 1 to 8 and between roxatidine acetate and the adjacent impurity peaks were all greater than 1.5, and the method had good specificity.

[0107] Example 3 Sensitivity of the HPLC separation and detection method of the present invention

[0108] The chromatographic conditions were the same as in Example 1.

[0109] Solution preparation method: Take appropriate amount of roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7 and related substance 8 respectively, dissolve them with solvent and dilute them step by step to make solutions of appropriate concentrations, and take the signal-to-noise ratio S / N ≥ 10 of the peak height of each component as the quantitative limit solution, and take the signal-to-noise ratio S / N ≥ 3 of each component as the detection limit solution.

[0110] The sensitivity results are shown in Table 2 below:

[0111] Table 2

[0112]

[0113]

[0114] The results showed that the method of the present invention was used to detect roxatidine acetate, related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8 with high sensitivity, and quantitative detection of each related substance could be completed at a level as low as ng.

[0115] Example 4 Durability of the HPLC separation and detection method of the present invention

[0116] Solution preparation: Weigh appropriate amounts of related substances 1-8 and roxatidine acetate reference substance respectively, dissolve and dilute with solvent to prepare a mixed solution containing about 2-4 μg of each related substance and about 2 mg of roxatidine acetate per 1 ml.

[0117] The durability results are shown in Tables 3, 4 and 5 below, respectively.

[0118] Table 3 Separation

[0119]

[0120] Table 4 Retention time (unit: min)

[0121]

[0122] Table 5 Theoretical plate number

[0123]

[0124] The results show that after slightly adjusting the chromatographic conditions of Example 1 of the present invention, the separation degree, retention time and theoretical plate number of each component still meet the requirements, and the durability of the method of the present invention is good.

[0125] Although the embodiments disclosed in the present invention are as above, the contents described are only embodiments adopted to facilitate understanding of the present invention and are not intended to limit the present invention. Any technician in the field to which the present invention belongs can make any modifications and changes in the form and details of the implementation without departing from the spirit and scope disclosed in the present invention, but the patent protection scope of the present invention shall still be subject to the scope defined in the attached claims.

Claims

1. A method for separating and / or detecting roxatidine acetate and its related substances, comprising the following features: using high performance liquid chromatography, the chromatographic column stationary phase is octadecylsilane bonded silica gel, the mobile phase is composed of phase A and phase B, phase A is potassium dihydrogen phosphate solution-methanol-acetonitrile, phase B is methanol-acetonitrile, the mobile phase is gradient elution, and the related substances are selected from any one of related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, related substance 6, related substance 7, and related substance 8 or a combination thereof:

2. The method according to claim 1, characterized in that The chromatographic column is Kromasil 100-5-C18, preferably Kromasil 100-5-C18, 4.6 mm×250 mm, 5 μm.

3. The method according to any one of claims 1 to 2, characterized in that: The column temperature of the chromatographic column is 25°C-45°C, preferably 30°C-40°C, the concentration of the potassium dihydrogen phosphate solution in the mobile phase A is 0.01mol / L-0.3mol / L, preferably 0.05mol / L-0.15mol / L, more preferably 0.05mol / L, the pH value of the potassium dihydrogen phosphate solution in the mobile phase A is adjusted to 5.5-6.5, preferably to 5.8-6.2, and particularly preferably, the use of hydrogen peroxide The pH value of the potassium dihydrogen phosphate solution is adjusted by potassium chloride solution, the volume ratio of potassium dihydrogen phosphate solution: methanol: acetonitrile in the mobile phase A is 81-99: 9.5-0.5: 9.5-0.5, preferably 84-96: 8-2: 8-2, more preferably 88-92: 6-4: 6-4, and the volume ratio of methanol to acetonitrile in the mobile phase B is 40-60: 60-40, preferably 45-55: 55-45, more preferably 50:

50.

4. The method according to any one of claims 1 to 3, characterized in that: The gradient elution procedure is: Preferably, the gradient elution procedure is:

5. The method according to any one of claims 1 to 4, characterized in that: The flow rate of the mobile phase is 0.8ml / min-1.4ml / min, preferably 1.0ml / min-1.2ml / min, the injection volume of the method is 25μl-75μl, preferably 40μl-60μl, more preferably 50μl, the method is equipped with an ultraviolet detector, and the detection wavelength of the ultraviolet detector is 190nm-210nm, preferably 195nm-205nm.

6. The method according to any one of claims 1 to 5, characterized in that: The peak elution order of the high performance liquid chromatography is related substance 1, related substance 2, related substance 3, related substance 4, related substance 5, roxatidine acetate, related substance 6, related substance 7, and related substance 8, wherein the separation between roxatidine acetate and the related substance 5 peak, the related substance 6 peak, and between the peaks of each related substance is greater than 1.

5.

7. The method according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: 1) Solution preparation: Solvent: water-acetonitrile (80:20); Test solution: Take an appropriate amount of roxatidine acetate, dissolve it in a solvent and dilute it to make a solution containing about 2 mg of roxatidine acetate per 1 ml; System suitability solution: Take appropriate amounts of related substances 1-8 and roxatidine acetate, dissolve and dilute with solvent to prepare a mixed solution containing about 2 mg of roxatidine acetate and about 2-4 μg of related substances 1 to 8 per 1 ml; 2) An octadecylsilane bonded silica gel column was used as the stationary phase, the column temperature was 30°C-40°C, the mobile phase consisted of phase A and phase B, phase A was 0.05 mol / L potassium dihydrogen phosphate solution (pH adjusted to 5.8-6.2 with potassium hydroxide solution)-methanol-acetonitrile (92-88:4-6:4-6), phase B was methanol-acetonitrile (50:50), the mobile phase was gradient elution, and the gradient elution program was as follows: Inject the eluted sample into the liquid chromatograph with an injection volume of 50 μl, a detection wavelength of 195-205 nm for the UV detector, and a flow rate of 1.0 ml to 1.2 ml per minute, and elute and record the chromatogram.

8. The method according to claim 7, characterized in that The method comprises the following steps: 1) Solution preparation: Solvent: water-acetonitrile (80:20); Test solution: Take an appropriate amount of roxatidine acetate, dissolve it in a solvent and dilute it to make a solution containing about 2 mg of roxatidine acetate per 1 ml; System suitability solution: Take appropriate amounts of related substances 1-8 and roxatidine acetate, dissolve and dilute with solvent to prepare a mixed solution containing about 2 mg of roxatidine acetate and about 2-4 μg of related substances 1 to 8 per 1 ml; 2) The chromatographic column Kromasil 100-5-C18, 4.6 mm × 250 mm, 5 μm was used as the stationary phase, the column temperature was 35°C, the mobile phase consisted of phase A and phase B, phase A was 0.05 mol / L potassium dihydrogen phosphate solution (pH adjusted to 6.0 with potassium hydroxide solution)-methanol-acetonitrile (90:5:5), phase B was methanol-acetonitrile (50:50), the mobile phase was gradient elution, and the gradient elution program was as follows: Inject the eluted sample into the liquid chromatograph with an injection volume of 50 μl, a detection wavelength of 200 nm for the UV detector, and a flow rate of 1.1 ml per minute to elute and record the chromatogram.

9. Use of the method according to any one of claims 1 to 8 for separating and / or detecting roxatidine acetate and its related substances.